Skip to main content
4SC AG logo

4SC AG — Investor Relations & Filings

Ticker · VSC ISIN · DE000A3E5C40 LEI · 391200QOKN7LGVP0RQ86 F Manufacturing
Open in API
Filings indexed 719 across all filing types
Latest filing 2007-02-06 Regulatory Filings
Country DE Germany
Listing F VSC

About 4SC AG

https://www.4sc.com/

4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.

Recent filings

Filing Released Lang Actions
4SC erhalt U.S.-Patent fur Medikamentenkandidaten SC12267
Regulatory Filings Classification · 100% confidence The document is a press release dated February 6, 2007, announcing that the biotech company 4SC AG received a U.S. Patent (No. 7,176,241) for its drug candidate SC12267, which is being developed for Rheumatoid Arthritis. This announcement details intellectual property protection, patent strategy, and provides general company information. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a specific corporate announcement regarding intellectual property and strategy, which fits best under the general category of Investor Information or Regulatory Filings. Since there is no specific code for 'Patent Grant Announcement' and the content is focused on corporate strategy and IP protection, it is most appropriately classified as a general Regulatory Filing (RNS) or potentially Investor Presentation (IP) if it were a slide deck, but given it's a news release about a specific corporate event (patent grant), RNS serves as the best general regulatory/corporate news category when a more specific one isn't available. However, since the content is highly specific to corporate strategy and IP, and is not a standard financial report, RNS is the most suitable fallback for non-standard corporate news releases.
2007-02-06 German
4SC nominates NFkB development candidate and presents new data
Regulatory Filings Classification · 100% confidence The document is a press release dated January 23, 2007, announcing a corporate development: the nomination of a new drug candidate (SC71570) for further development based on positive preclinical data presented at an upcoming conference. It discusses drug pipeline progress, scientific mechanisms (NFkB inhibition), and potential market size. This content is characteristic of an announcement related to research and development progress, which often falls under general investor relations or regulatory news. Since it is not a formal financial report (10-K, IR, ER, MRQ), a management discussion (MDA), or a specific legal/governance filing, the most appropriate category is the general 'Regulatory Filings' (RNS) as a catch-all for significant corporate news that doesn't fit the highly specific financial or governance codes, or potentially 'LTR' if it were about legal proceedings, but here it is about R&D progress. Given the options, RNS is the best fit for a general corporate news announcement about R&D milestones.
2007-01-23 English
4SC nominiert NFkB-Entwicklungskandidaten und prasentiert neue Daten auf der GTCBio - Konferenz
Legal Proceedings Report Classification · 99% confidence The document is a press release dated January 23, 2007, announcing that 4SC AG will present positive data on its NFkB inhibitor (SC71570) at the '5th GTCBio Cytokines & Inflammation Conference'. It details the nomination of SC71570 as a development candidate, its promising activity compared to Methotrexate in an animal model for Rheumatoid Arthritis, and the potential therapeutic areas. This is a corporate announcement regarding R&D progress and presentation of scientific data, not a formal regulatory filing like a 10-K, an earnings release (ER), or a full investor presentation (IP). It fits best as a general corporate announcement or news item. Since it is a specific announcement about corporate activity (drug development milestone and conference presentation), and not a standard financial report or mandatory filing, it falls under the general category of Regulatory Filings (RNS) as a fallback for specific corporate news that doesn't match other categories, although it is essentially a press release detailing scientific progress. Given the options, RNS (Regulatory Filings/General Announcement) is the most appropriate fit for a non-financial, non-management change press release detailing R&D milestones.
2007-01-23 German
4SC and XL TechGroup found new company for the development of biofilm inhibitory substances
Regulatory Filings Classification · 95% confidence The document is an 'Ad hoc announcement' dated December 28, 2006, transmitted via DGAP, which is a mechanism for disseminating regulatory information in Germany (§ 15 WpHG). The content describes a significant business event: the formation of a joint venture company (QuoNova) between 4SC AG and XL TechGroup for the development of biofilm inhibitory substances. This type of announcement, detailing a major strategic transaction or corporate development that is not a standard periodic financial report (like 10-K or IR) or a specific insider trade/dividend notice, typically falls under general regulatory disclosure or miscellaneous corporate news. Since it is a material, non-scheduled announcement concerning business operations and strategy, and it doesn't fit the specific definitions for M&A (TAR), Capital Change (CAP/SHA), or Director's Dealing (DIRS), the most appropriate general category for significant, non-standard regulatory disclosures is 'Regulatory Filings' (RNS), which serves as the fallback for miscellaneous regulatory announcements not covered by other specific codes.
2006-12-28 English
4SC AG - a Landmark in the Land of Ideas 2007
Report Publication Announcement Classification · 99% confidence The document is a short press release dated December 15, 2006, announcing that 4SC AG has been selected as a 'Landmark in the Land of Ideas 2007'. It details an upcoming public event and provides general company background. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a report itself (AR, IR). Since it is a general corporate announcement that doesn't fit the specific categories like AGM-R, MANG, DIRS, or DIV, and it is not explicitly announcing the publication of a major report (which would suggest RPA), the most appropriate fallback category is Regulatory Filings (RNS) for miscellaneous corporate news releases.
2006-12-15 English
4SC AG - ein Ort im Land der Ideen 2007
Regulatory Filings Classification · 100% confidence The document is a short news release dated December 15, 2006, announcing that 4SC AG has been selected as one of the 'Places in the Land of Ideas 2007' ('Ort im Land der Ideen 2007') under the patronage of the Federal President. It describes a specific event planned for August 14, 2007, and provides general company background. This is not a formal regulatory filing like a 10-K, IR, or ER. It is a general corporate announcement regarding an award/recognition, which does not fit into the specific categories like AGM-R, DIRS, DIV, or CAP. Given the nature of the announcement—a general corporate update that doesn't fit the highly specific financial or governance categories—the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general announcement category.
2006-12-15 German

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.